Barclays Maintains Equal-Weight on Insulet, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Equal-Weight rating on Insulet (NASDAQ:PODD) and lowers the price target from $213 to $200.

May 13, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays maintains an Equal-Weight rating on Insulet but lowers the price target from $213 to $200, indicating a cautious but not bearish outlook.
The reduction in price target by Barclays reflects a slightly less optimistic view on Insulet's stock value, potentially due to revised earnings expectations or market conditions. While maintaining the Equal-Weight rating suggests that Barclays does not see significant downside risk, the lowered price target could lead to short-term negative sentiment among investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100